Curiously, VPRBP inhibition potentially produces two opposing effects on tumor development by suppressing tumor cell growth by activation of p53 (Fig. 4a–c) while also allowing tumor cells to evade immunosurveillance through increased PD-L1 levels (Figs. 1–3). This evidence concerns the gene DCAF1 and neoplasm.